- VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies.
- The company entered the NASDAQ market in June 2026 following its completed business combination with Voyager Acquisition Corp., giving VERAXA access to the U.S. public markets as it advances its development programs.
- BiTAC is designed as an “AND-gated” therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated.
- VERAXA has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June.
- Recent corporate developments include the appointment of Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer, adding financial and antibody-development expertise.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones that have expanded the company’s focus around its proprietary BiTAC(R) platform.
The Swiss biotechnology company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement for up to $50 million. The company said the financing was intended to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development.
Since then, VERAXA has continued building the infrastructure around its drug-development strategy. Most recently, the company appointed Raju Willener as chief financial officer. Willener brings more than three decades of experience spanning investment banking, corporate finance, asset management and capital markets. Before joining VERAXA, he was director of corporate development at Exentis Group AG and subsequently became its CFO in 2025. Earlier in his career, he held senior positions involving investment portfolios exceeding CHF 30 billion in assets under management.
The appointment comes as VERAXA attempts to move its technology from proof-of-concept work toward a broader therapeutic pipeline. At the center of that effort is BiTAC, short for Bi-targeted Tumor-Associated Cytotoxicity. The technology differs from conventional bispecific antibodies by separating its targeting functions into two complementary molecules.
The intended mechanism is conditional. Each component by itself should have limited cytotoxic activity, while simultaneous engagement of both targets on the same tumor cell is designed to establish the active therapeutic mechanism. VERAXA describes this as an “AND-gated approach.”
For T-cell engagers, the architecture is intended to restrict activation of T cells to cancer cells carrying both selected targets. The company’s stated objective is to improve tumor selectivity and potentially widen the therapeutic window.
The concept has already generated early experimental data. At the 2026 American Association for Cancer Research Annual Meeting, VERAXA presented results from its most advanced BiTAC-TCE program. According to the company, the candidate showed activity against cells carrying both target molecules while sparing cells expressing only one target. VERAXA also reported in-vivo results showing comparable efficacy to a conventional TCE alongside an improved safety profile.
VERAXA has also extended the BiTAC concept into antibody-drug conjugates, or ADCs. In June, the company reported an in-vitro proof of concept for its BiTAC-ADC platform and said laboratory testing demonstrated selective activity against breast-cancer cells, including dose-dependent killing in three-dimensional tumor spheroids. The company subsequently used the data in discussions around potential partnering opportunities.
That dual-platform strategy places VERAXA within two active areas of oncology research. ADCs combine an antibody with a potent cytotoxic payload, allowing targeted delivery of cancer-killing compounds. The technology has attracted significant pharmaceutical investment as developers seek to improve tumor targeting, payload delivery and tolerability.
Grand View Research estimates that the global ADC market could reach $32.11 billion by 2033, compared with a projected compound annual growth rate of 10.49% from 2025 through 2033.
VERAXA is developing additional technologies around ADC construction, including site-specific conjugation, click chemistry, hydrophilic payload-linker systems and tumor-selective approaches to payload activation. These technologies provide a broader development base beyond BiTAC itself.
The company’s pipeline also includes VX-A901, a clinical-stage monoclonal antibody targeting FLT3 for acute myeloid leukemia. The program has generated Phase I clinical data, while VERAXA has said it intends to pursue an out-licensing strategy as its development emphasis increasingly shifts toward conditionally active, dual-targeting modalities.
Alongside the pipeline, VERAXA has been strengthening its scientific organization. The company appointed Christoph Erkel, Ph.D., as chief scientific officer, while recent regulatory work with Germany’s Paul-Ehrlich-Institute provided feedback on the proposed nonclinical development strategy for its BiTAC-TCE program. VERAXA has also expanded its intellectual-property portfolio around its technology platforms.
Another recent development has broadened the company’s technology interests beyond ADCs and TCEs. In August, VERAXA and Secarna Pharmaceuticals announced an in-vitro proof-of-concept milestone in an antibody-oligonucleotide conjugate alliance, combining VERAXA’s conjugation capabilities with Secarna’s oligonucleotide technology.
The company has also been expanding intellectual-property protection. In July, VERAXA reported more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families, with additional applications covering BiTAC-TCE and BiTAC-ADC technologies.
For more information, visit the company’s website at www.Veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
